GlassScriptPhysician profile
Marcy L Canary
NPI 1053400739
$8,966.66
in general payments reported to CMS, 2019-2025
52 companies · $986 in 2025
The $986 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $354 · 2021: $681 · 2022: $1,891 · 2023: $2,126 · 2024: $2,020 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,115 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,115.03 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $809.11 | 2019-2025 | Opdualag, Opdivo, Augtyro |
| Daiichi Sankyo INC. | $679.52 | 2022-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $606.51 | 2019-2025 | |
| Pfizer INC. | $606.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $594.41 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $583.46 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $506.89 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $472.24 | 2021-2025 | Libtayo |
| Celgene Corporation | $460.96 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Amgen INC. | $359.72 | 2019-2023 | Kyprolis, Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $265.31 | 2023-2024 | Ninlaro, Alunbrig, Fruzaqla |
| Lilly USA, LLC | $242.38 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $237.10 | 2019-2025 | Bavencio |
| Eisai INC. | $224.69 | 2022-2024 | |
| Astellas Pharma US INC | $219.64 | 2022-2025 | Xospata, Xtandi, Padcev |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $185.11 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Genentech USA, INC. | $170.44 | 2021-2025 | Polivy, Tecentriq, Lunsumio |
| Genzyme Corporation | $162.70 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $120.48 | 2019-2023 | Imbruvica, Epkinly |
| Seagen INC. | $104.67 | 2019-2023 | Tukysa |
| Beigene USA, INC. | $103.00 | 2022-2023 | Brukinsa |
| Servier Pharmaceuticals LLC | $100.53 | 2021-2024 | |
| Exelixis INC. | $91.16 | 2019-2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $81.25 | 2021-2022 | |
| Tersera Therapeutics LLC | $74.23 | 2022-2024 | Zoladex |
| Gilead Sciences, INC. | $68.48 | 2022-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $66.78 | 2022-2024 | Xpovio |
| Abbvie INC. | $62.03 | 2024-2025 | |
| Puma Biotechnology, INC. | $52.65 | 2023-2024 | Nerlynx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.17 | 2019 | |
| Adaptive Biotechnologies Corporation | $47.80 | 2022-2023 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $46.75 | 2022-2023 | Monoferric |
| Taiho Oncology, INC. | $46.47 | 2019-2023 | |
| Adc Therapeutics America, INC. | $38.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $36.29 | 2022 | |
| Immunogen, INC. | $35.89 | 2023-2024 | Elahere, Elahere |
| Foundation Medicine, INC. | $34.16 | 2023 | |
| Myriad Genetic Laboratories, INC. | $32.58 | 2023 | Myrisk |
| Array Biopharma INC | $26.34 | 2025 | Braftovi, Tukysa, Mektovi |
| Sumitomo Pharma America, INC. | $25.72 | 2024 | Orgovyx |
| Cti Biopharma Corp. | $24.81 | 2023 | Vonjo |
| Iovance Biotherapeutics, INC. | $23.72 | 2025 | Amtagvi |
| Sobi, INC | $22.15 | 2024 | |
| Mirati Therapeutics, INC. | $21.57 | 2023 | Krazati |
| Blueprint Medicines Corporation | $21.24 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.30 | 2024 | Somatuline Depot, Onivyde |
| Alexion Pharmaceuticals, INC. | $18.83 | 2023 | Ultomiris |
| Verastem, INC. | $17.89 | 2019 | |
| Tg Therapeutics, INC. | $17.28 | 2022 | |
| Rigel Pharmaceuticals, INC. | $16.10 | 2020 | |
| Morphosys, US INC. | $15.93 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.03 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Canary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.